Passage Bio to Participate in Chardan's 9th Annual Genetic Medicines Conference

Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company dedicated to enhancing the lives of patients suffering from neurodegenerative diseases, has announced the participation of its President and CEO, Dr. Will Chou, in the Chardan 9th Annual Genetic Medicines Conference. This event is set for October 21, 2025, at 3:30 p.m. ET in New York City. The discussion will cover advancements in genetic medicines, where Dr. Chou will likely share insights on Passage Bio’s innovative approaches and research breakthroughs. A live webcast of the panel will be accessible through the Investors & News section of Passage Bio’s website, with a replay available for 90 days post-event.

Passage Bio focuses primarily on developing one-time genetic therapies aimed at addressing the root causes of neurodegenerative conditions. Its lead candidate, PBFT02, targets diseases such as frontotemporal dementia by increasing progranulin levels to restore lysosomal function and mitigate disease progression. This therapeutic strategy underscores the company’s commitment to harnessing genetic medicine to transform treatment paradigms for devastating neurological disorders.

The participation in the conference aligns with Passage Bio's mission to ensure better health outcomes for patients and their families affected by neurodegenerative diseases. The company is actively contributing to the conversation surrounding advancements in genetic therapies, emphasizing the importance of innovative treatments in the healthcare landscape.

For individuals interested in learning more about Passage Bio's endeavors and commitment to neurological health, additional information can be found on the company’s website. Investors and media inquiries can be directed to Stuart Henderson and Mike Beyer, respectively, for further engagement.

Passage Bio, Inc. (NASDAQ: PASG) is making a significant move by participating in Chardan’s 9th Annual Genetic Medicines Conference on October 21, 2025. The presence of Dr. Will Chou, the company’s CEO, at this event will likely provide valuable insights into the strategic direction of Passage Bio and its innovative pipeline targeting neurodegenerative diseases.

Investors should closely monitor the outcomes of the panel discussion, especially regarding the lead product candidate, PBFT02, aimed at treating frontotemporal dementia. The focus on elevating progranulin levels to restore lysosomal function presents a promising therapeutic avenue and could set Passage Bio apart in a crowded market of neurodegenerative treatments. This differentiation is critical in an industry that often deals with limited successful outcomes in clinical stages.

As Passage Bio continues to navigate through the clinical trials and further innovations, the upcoming conference offers a prime opportunity for investors to gauge the company's commitment to delivering impactful solutions for patients. Given that neurodegenerative diseases represent a growing area of concern with significant unmet needs, Passage Bio’s strategic focus could position it advantageously for future growth and collaborations.

Investors should consider tracking the stock leading up to and following the conference. Market responses to industry conferences often reflect broader investor sentiment regarding upcoming product announcements and advancements in clinical trials. A positive reaction from the market could indicate growing confidence in Passage Bio's trajectory and its innovative approach to genetic medicines.

In summary, investors interested in the biotech sector and particularly in neurodegenerative disease treatments should keep an eye on Passage Bio as it participates in this important conference. Analyzing the discussion points and any data shared by the executives could provide key indications of future performance and market potential.